We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

EUROIMMUN AG

EUROIMMUN is an international provider of medical laboratory products for autoimmune, infection, allergy and molecula... read more Featured Products: More products

Download Mobile App




Automated Microscope Classifies IIF Patterns in Autoimmune Dermatoses

By LabMedica International staff writers
Posted on 02 May 2023
Print article
Image: Exemplary images of IIF on esophagus and salt-split skin (Photo courtesy of EUROIMMUN)
Image: Exemplary images of IIF on esophagus and salt-split skin (Photo courtesy of EUROIMMUN)

Autoimmune bullous dermatoses (AIBD) are a diverse group of autoantibody-driven conditions characterized by blistering and erosion of the skin and mucous membranes, including pemphigus diseases, pemphigoid diseases, and dermatitis herpetiformis. Differentiating between disease sub-types is essential for making treatment decisions. Indirect immunofluorescence (IIF) microscopy using tissue sections of the esophagus and salt-split skin is one of the most sensitive screening methods for initially differentiating AIBD. IIF on esophagus identifies autoantibodies against epithelial and endomysial antigens, while IIF on salt-split skin differentiates autoantibodies against the basement membrane zone. However, interpreting the complex IIF patterns can be challenging and is not well standardized.

In a joint study, scientists at EUROIMMUN (Lübeck, Germany) and the University of Lübeck (Lübeck, Germany) have developed and assessed a computer-aided system for classifying IIF patterns on esophagus and salt-split skin samples. The scientists created the training datasets by incubating biochip slides containing millimeter-sized tissue sections with various dilutions of patient serum samples and controls. Subsequently, the team used the EUROPattern Microscope 1.5 to acquire images. The results of the computer-aided evaluation were compared with findings from manual evaluations by experienced IIF technicians.

Automated IIF evaluation on esophagus and salt-split skin presents a challenge, as the small structures necessary for classification are only present in certain areas of the tissue substrates. Standard deep networks are not suitable for processing these images due to computer memory limitations and the number of available training images. Consequently, the researchers employed segmentation to focus the classification networks on the essential regions. The developed algorithms demonstrated high accuracy for pattern classification on esophagus and salt-split skin, with over 95% agreement with visual reading results. The positive predictive agreement was above 97% for all positive IF patterns on both tissue substrates, while the negative predictive agreement was at least 95% for all patterns.

The researchers concluded that deep networks can be adapted for evaluating complex tissue substrates by incorporating the segmentation of relevant regions into the prediction process. These classifiers offer an excellent enhancement to AIBD screening methods and can reduce the workload for professionals when interpreting tissue sections in IIF testing.

Related Links:
EUROIMMUN 
University of Lübeck 

New
Gold Member
Human Chorionic Gonadotropin Test
hCG Quantitative - R012
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Chagas Disease Test
LIAISON Chagas
New
Luteinizing Hormone Assay
DRG LH-Serum ELISA Kit

Print article

Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.